Primary cutaneous maringal zone lymphoproliferative disorder

Last updated on: 31.08.2025

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The concept of primary cutaneous marginal zone lymphoma (pcMZL) has been adapted several times in recent years. In 2005, Willemze et al. defined pcMZL as an indolent lymphoma and as part of the group of extranodular B-cell marginal zone lymphomas. In the current version of the WHO classification of lymphoid neoplasms, it was classified as an independent entity in distinction to other marginal zone lymphomas (Alaggio R et al. 2022). In the meantime, pcMZL has been downgraded from a lymphoma to a lymphoproliferative disorder (pcMZLPD) due to its indolent behavior, as the disease-specific survival rate is almost 100% without the need for aggressive therapies. In this respect, various authors refer to this lymphoproliferative entity not as a lymphoma but as a pcMZLPD, a lymphoproliferative disorder (Cankaya R et al. 2025).

LiteratureThis section has been translated automatically.

  1. Alaggio R et al. (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720-1748.
  2. Cankaya R et al. (2025) How to treat primary cutaneous B cell lymphoma - Results from a monocentric cohort study on 98 patients. J Dtsch Dermatol Ges 23:822-830.

Last updated on: 31.08.2025